Try GOLD - Free
COVID-19 Likely To Linger On Till 2021?
Bio Spectrum
|August 2020
Easy mode of transmission, nature of the virus, population density, environmental condition, social culture are the major contributors to the rapid spreading of COVID-19 across the globe. But in order to break the chain of transmission, one needs to understand the transmission dynamics of this ongoing pandemic, which is somehow unclear.

Over the previous centuries, global pandemics of infectious diseases, such as smallpox, cholera, and influenza, have periodically threatened the survival of entire global population. By the mid-twentieth century, safe, effective, and affordable vaccines and the increasing availability of antibiotics had reduced the toll of infectious diseases in the high-income countries (HICs). Not until the second half of the twentieth century did large scale efforts begin to better control infectious diseases in low and middle-income countries (LMICs), where the infectious disease burden was greatest and highly varied.
The decline of the vaccine-preventable diseases has contributed to a recognition of the potential for using vaccines to prevent other infectious diseases, including acquired immune deficiency syndrome (HIV/AIDS), tuberculosis (TB), malaria, hepatitis C, and a variety of neglected tropical diseases (NTDs). However, emerging pandemic viral infections remain a constant threat.
The most common examples of viral infections include SARS (severe acute respiratory syndrome), MERS (middle east respiratory syndrome), and Ebola and Zika viruses as well as, perennially, influenza, and chikungunya infections. Compared with antibiotics to treat bacterial infections, relatively few antiviral drugs have been developed to treat these emerging viral infections. Therefore, the most important intervention is to break the chain of transmission.
This need has become all the more necessary with the recent COVID-19 outbreak. Easy mode of transmission, nature of the virus, population density, environmental condition, social culture are the major contributors to its rapid spreading across the globe. But in order to break the chain of transmission, one needs to understand the transmission dynamics of this ongoing pandemic.
This story is from the August 2020 edition of Bio Spectrum.
Subscribe to Magzter GOLD to access thousands of curated premium stories, and 9,500+ magazines and newspapers.
Already a subscriber? Sign In
MORE STORIES FROM Bio Spectrum

Bio Spectrum
WHO certifies Suriname malaria-free
Suriname became the first country in the Amazon region to receive malaria-free certification from the World Health Organization (WHO).
1 min
August 2025

Bio Spectrum
Torrent Pharma buys controlling stake in JB Pharma from KKR for Rs 25,689 Cr valuation
Ahmedabad-based Torrent Pharmaceuticals and global investment firm KKR have announced that Torrent has entered into definitive agreements to acquire controlling stake in Mumbai-based J. B. Chemicals and Pharmaceuticals (JB Pharma) from KKR at an Equity Valuation of Rs 25,689 crore (on fully diluted basis), followed by a merger of the two entities.
1 min
August 2025
Bio Spectrum
Suraksha Diagnostics injects Rs 22 Cr to establish Eastern India's largest genomics lab
Suraksha Diagnostics, one of the leading diagnostics chains in Eastern India, has launched one of the largest and a state-of-theart genomics lab in Eastern India.
1 min
August 2025
Bio Spectrum
Illumina buys SomaLogic for $425 M to accelerate proteomics business
Illumina, Inc. has entered into a definitive agreement with Standard BioTools under which Illumina will acquire SomaLogic, a leader in data-driven proteomics technology, and other specified assets for $350 million in cash payable at closing, subject to customary adjustments, plus up to $75 million in near-term performance-based milestones and performance-based royalties.
1 min
August 2025

Bio Spectrum
Kashmik Formulation to expand capacity, eyes Rs 100 Cr revenue in FY26
Kashmik Formulation, a pharmaceutical manufacturing company headquartered in Ahmedabad, has announced significant expansion plans aimed at increasing production capacity, strengthening its presence in international markets, and enhancing operational efficiencies through automation.
1 min
August 2025
Bio Spectrum
WHO highlights risks associated with use of semaglutide medicines
The World Health Organisation (WHO) is alerting healthcare professionals and regulatory authorities to the risk of non-arteritic anterior ischemic optic neuropathy (NAION) associated with the use of semaglutide medicinesOzempic, Rybelsus, and Wegovy.
1 min
August 2025

Bio Spectrum
Lamark Biotech secures Rs 6.5 Cr to accelerate development of thermostable insulin
Lamark Biotech, an innovation-led biopharma startup, has raised Rs 6.5 crore in a PreSeries A round led by IAN Group, including IAN Alpha Fund, powered by BioAngels, Dr Vinayender Tulla, Dr Nita Roy, and Venkataraman KNK, domain experts of IAN's angel investors led the round.
1 min
August 2025

Bio Spectrum
AstraZeneca invests Rs 166 Cr to expand Global Hub in Bengaluru
AstraZeneca, a global, science-led biopharmaceutical company, has announced the expansion of its state-of-the-art Global Hub in Bengaluru, strengthening its presence in India.
1 min
August 2025

Bio Spectrum
Novo Nordisk launches injectable Semaglutide for weight management in India
Novo Nordisk, a leading global healthcare company headquartered in Denmark with over a 100-year legacy of chronic disease care, has announced the launch of Wegovy (injectable Semaglutide) in India.
1 min
August 2025

Bio Spectrum
Can Policy Reforms & Investments Trigger India's MedTech MAKEOVER?
India's MedTech sector has long been import-dependent. The Centre is now working to change this by positioning the country as an export-oriented manufacturing hub. A series of policies and investments have been introduced to support this shift. Have these made an impact? What steps are necessary to strengthen India's position in the global medical technology (MedTech) landscape? Let's find out.
12 mins
August 2025
Translate
Change font size